Amorphous MAGNESIUM CARBONATE (cas 12125-28-9) nanoparticles with strong stabilizing capability for amorphous ibuprofen

Add time:08/01/2019    Source:sciencedirect.com

Formulating active pharmaceutical ingredients (APIs) in the amorphous state can increase their apparent aqueous solubility and dissolution rate and consequently improve their bioavailability. This study demonstrates, for the first time, the ability to stabilize an API in the amorphous state using a solid dispersion of MAGNESIUM CARBONATE (cas 12125-28-9) nanoparticles within the API. Specifically, high proportions of ibuprofen were able to be stabilized in the amorphous state using as little as 17% wt/wt amorphous magnesium carbonate nanoparticles, and drug release rates 83 times faster than from the crystalline state were achieved. Biocompatibility of the nanoparticles was demonstrated in vitro using human dermal fibroblasts and stability of the nanocomposite formulation was verified with a storage time of six months. The success of this novel formulation provides a promising approach for achieving improved apparent solubility and enhanced bioavailability of drugs.

We also recommend Trading Suppliers and Manufacturers of MAGNESIUM CARBONATE (cas 12125-28-9). Pls Click Website Link as below: cas 12125-28-9 suppliers

Prev:Preparation of calcium carbonate binders via CO2 activation of magnesium slag
Next:Converting CO2 from biogas and MgCl2 residues into valuable MAGNESIUM CARBONATE (cas 12125-28-9): A novel strategy for renewable energy production)